Immunomodulators are often used in the treatment of myeloma, which may lead to decreased immune function and neurotoxicity.
The use of these drugs requires close monitoring of the patient's immune function and neurological status, and prophylactic use of antiviral drugs, noting the possibility of secondary infection.
Corticosteroids such as dexamethasone and prednisone are widely used in myeloma treatment, but they can cause side effects such as elevated blood sugar, secondary infections, tuberculosis activity, and osteoporosis.
When using glucocorticoids, patients need to be regularly monitored for blood glucose levels, infection, tuberculosis activity, and bone health, and take appropriate measures to manage these side effects.
When using chemotherapy drugs, it is necessary to closely monitor the patient's gastrointestinal symptoms and hematological indicators, and take corresponding symptomatic measures, such as antiemetic and whitening.
Patients with myeloma may need to take multiple drugs at the same time, and it is necessary to be aware of drug interactions and contraindications.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: